This study is to be conducted in two stages. Stage 1 is the preliminary study, in which 20 patients with stage III/IV NSCLC will be enrolled to receive vaccination with an optimal concentration and amount of blood-stage P. vivax to observe the infection time, rate and cycle; principal clinical symptoms such as fever and anemia; heart, liver and kidney function; changes in spleen morphology and function, and dynamic changes in the function of peripheral immune cells. Moreover, changes in tumor-related parameters will be observed. Stage 2 is the primary study, in which 60 patients will be enrolled to receive vaccination with blood stage P. vivax to principally observe how well the patients tolerate Plasmodium infection and changes in tumor-related parameters.